Vireo Growth (VREOF) Long-Term Investments (2025 - 2026)

Vireo Growth (VREOF) reported Long-Term Investments of $6.0 million for Q1 2026, little changed sequentially from $6.0 million in Q4 2025.

Vireo Growth (VREOF) Long-Term Investments (2025 - 2026) Analysis & Trends

Vireo Growth (VREOF) has 2 years of Long-Term Investments data on file, last reported at $6.0 million in Q1 2026.

For the quarter ending Q1 2026, Long-Term Investments changed N/A year-over-year to $6.0 million; the trailing twelve-month figure through Mar 2026 stood at $6.0 million (changed N/A YoY), and the FY2025 full-year result was $6.0 million, changed N/A from the prior year.
Long-Term Investments steadied at $6.0 million in Q1 2026, from $6.0 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $13.1 million in Q2 2025 to a low of $6.0 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Haleon	88.07 Bn	86.20 Bn	-	-
2	Teva Pharmaceutical Industries	35.75 Bn	32.01 Bn	1.97 Bn	-
3	Zoetis	31.84 Bn	29.90 Bn	1.62 Bn	-
4	Takeda Pharmaceutical	27.18 Bn	23.12 Bn	4.39 Bn	56.09 Mn
5	United Therapeutics	23.09 Bn	20.93 Bn	648.10 Mn	1.32 Bn
6	RedHill Biopharma	21.32 Bn	21.32 Bn	-	12.05 Mn
7	Viatris	19.96 Bn	18.16 Bn	1.16 Bn	-
8	Neurocrine Biosciences	17.66 Bn	16.34 Bn	800.70 Mn	146.10 Mn
9	Elanco Animal Health	12.44 Bn	12.02 Bn	785.00 Mn	-
10	Vireo Growth	10.53 Bn	10.38 Bn	59.30 Mn	6.00 Mn

Download Data